RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $84

Moomoo NewsJan 7 09:35 ET · Ratings

Legend Biotech Price Target Lowered to $84 From $86 at RBC Capital

TipRanksJan 7 08:50 ET

BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90

Moomoo NewsJan 7 08:35 ET · Ratings

Promising Growth Trajectory and Market Expansion Justify Buy Rating for Legend Biotech

TipRanksJan 7 07:56 ET · Ratings

RBC Trims Price Target on Legend Biotech to $84 From $86, Keeps Outperform Rating

MT NewswiresJan 7 07:54 ET · Ratings

CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.

CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides

Sina Hong Kong StocksJan 3 03:36 ET